Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3821 in Moderate to Severe Rheumatoid Arthritis
CTR20231260Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tqh3821 in rheumatoid arthritis (RA), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2023; status: terminated.
02
Drugs
tqh3821
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20231260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231260.